Mineralys Selling General Administrative from 2010 to 2024
| MLYS Stock | 12.53 0.66 5.56% |
Selling General Administrative | First Reported 2010-12-31 | Previous Quarter 14.3 M | Current Value 15 M | Quarterly Volatility 5 M |
Check Mineralys Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mineralys Therapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 10.9 M, Depreciation And Amortization of 159.5 K or Interest Expense of 2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.36. Mineralys financial statements analysis is a perfect complement when working with Mineralys Therapeutics, Valuation or Volatility modules.
Mineralys | Selling General Administrative |
Latest Mineralys Therapeutics,'s Selling General Administrative Growth Pattern
Below is the plot of the Selling General Administrative of Mineralys Therapeutics, Common over the last few years. It is Mineralys Therapeutics,'s Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mineralys Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
| Selling General Administrative | 10 Years Trend |
|
Selling General Administrative |
| Timeline |
Mineralys Selling General Administrative Regression Statistics
| Arithmetic Mean | 2,853,653 | |
| Geometric Mean | 1,066,325 | |
| Coefficient Of Variation | 173.67 | |
| Mean Deviation | 3,463,312 | |
| Median | 532,000 | |
| Standard Deviation | 4,955,857 | |
| Sample Variance | 24.6T | |
| Range | 14.5M | |
| R-Value | 0.69 | |
| Mean Square Error | 13.8T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | 767,716 | |
| Total Sum of Squares | 343.8T |
Mineralys Selling General Administrative History
About Mineralys Therapeutics, Financial Statements
Mineralys Therapeutics, shareholders use historical fundamental indicators, such as Selling General Administrative, to determine how well the company is positioned to perform in the future. Although Mineralys Therapeutics, investors may analyze each financial statement separately, they are all interrelated. The changes in Mineralys Therapeutics,'s assets and liabilities, for example, are also reflected in the revenues and expenses on on Mineralys Therapeutics,'s income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Selling General Administrative | 14.3 M | 15 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.